$TCDA News
Last published 4y ago
- 4y agoTCDATricida Provides Strategic UpdateBusiness WireTricida, Inc. (NASDAQ:TCDA), announced today that the Board of Directors has authorized Tricida to initiate a review of strategic alternatives to maximize stakeholder value. To facilitate this review, Tricida has
- 4y agoTCDATricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of VeverimerBusiness WireWebcast today at 8:00 am Eastern Time Tricida, Inc. (NASDAQ:TCDA) announced today the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer's ability to slow CKD progression
- 4y agoHTGCTCDATricida Announces $125 Million Debt Facility with Hercules CapitalBusiness WireTricida, Inc. (NASDAQ:TCDA) announced today that it has entered into a debt facility with Hercules Capital, Inc. (NYSE:HTGC), a leader in customizing debt financing for companies in the life sciences and
- 4y agoTCDATricida Announces the Selection of the VALOR-CKD Trial for an Oral Presentation in the High-Impact Clinical Trials Session at ASN Kidney Week 2022Business WireTricida, Inc. (NASDAQ:TCDA) announced today that a late-breaking clinical trial abstract on the Phase 3, VALOR-CKD renal outcomes trial has been selected by the American Society of Nephrology (ASN) and the Kidney Week Education Committee for oral presen
- 4y agoTCDATricida to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceBusiness WireTricida, Inc. (NASDAQ:TCDA) today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference. Tricida will provide a company overview, business update and progress on the company's key initiatives. The presentation
- 4y agoTCDATricida Announces Second Quarter 2022 Financial ResultsBusiness WireWebcast Today at 4:30 pm Eastern Time Tricida, Inc. (NASDAQ:TCDA) announced today financial results for the three and six months ended June 30, 2022 and provided an update on key initiatives. Business Update Tricida announced in May 2022 that
- 4y agoTCDATricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Monday, August 8, 2022GlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) today announced that it will report its second quarter 2022 financial results after the close of market on Monday, August 8, 2022. Tricida will host a webcast a
- 4y agoTCDATricida Announces Administrative Stop of the VALOR-CKD TrialGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) announced today that as anticipated it is stopping its VALOR-CKD renal outcomes trial early for administrative reasons pursuant to the existing study protocol to
- 4y agoTCDATricida to Report First Quarter Financial Results and Host Conference Call and Webcast on Tuesday, May 10, 2022GlobeNewswireSOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) today announced that it will report its first quarter 2022 financial results after the close of market on Tuesday, May 10, 2022. Tricida will host a conference c
- 4y agoTCDATricida to Present at the Needham Virtual Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) announced today that it will present at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022 at 10:30 am Pacific Time / 1:30 pm East
- 4y agoTCDATricida Announces Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewswireWebcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) announced today financial results for the three months and year ended December 31, 2021 and provided an update on key
- 4y agoTCDATricida to Report Fourth Quarter Financial Results and Host Conference Call and Webcast on Tuesday, March 29, 2022GlobeNewswireSOUTH SAN FRANCISCO, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) today announced that it will report its fourth quarter and year-end 2021 financial results after the close of market on Tuesday, March 29, 2022. Tricida will h
- 4y agoTCDATricida Provides Update on Timing of Top-Line Data for the VALOR-CKD Trial Based on Conflict in UkraineGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administere
- 4y agoTCDATricida to Participate in Cowen 42nd Annual Health Care ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administere
- 4y agoTCDAToragen, Inc. Announces Appointment of Dr. Sandra Coufal, M.D. as CEOBusiness WireToragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV") Toragen Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targetin
- 4y agoTCDATricida to Present at the 40th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright BIOCONNECT Virtual ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 7:30 am PT / 10:30 am ET. Gerrit Klae
- 4y agoTCDATricida to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 am PT / 1:30 pm ET. Gerrit Klae
- 4y agoTCDATricida Raises $42 Million in Registered Direct Equity FinancingGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered
- 5y agoTCDATricida Announces Third Quarter 2021 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered
- 5y agoTCDATricida to Report Third Quarter Financial Results and Host Conference Call and Webcast on Monday, November 8, 2021GlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) today announced that it will report its third quarter 2021 financial results after the close of market on Monday, November 8, 2021. Tricida will host a conferen
- 5y agoTCDATricida to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference. Tricida will provide a company overview, business update
- 5y agoTCDATricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Monday, August 9, 2021GlobeNewswireSOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) today announced that it will report its second quarter 2021 financial results after the close of market on Monday, August 9, 2021. Tricida will host a conferenc
- 5y agoTCDATricida to Present at the Goldman Sachs 42nd Annual Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) today announced that it will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 12:50 pm PT / 3:50 pm ET. Gerri
- 5y agoTCDATricida Announces First Quarter 2021 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, May 06, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer
- 5y agoTCDATricida, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 6, 2021 / Tricida, Inc. (NASDAQ:TCDA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 4:30 PM Eastern Time. To listen to the event live or access a replay o
- 5y agoTCDATricida to Report First Quarter Financial Results and Host Conference Call and Webcast on Thursday, May 6, 2021GlobeNewswireSOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) today announced that it will report its first quarter 2021 financial results after the close of market on Thursday, May 6, 2021. Tricida will host a conference
- 5y agoTCDATricida to Present at the Needham Virtual Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 20th Annual Needham Virtual Healthcare Conference on Tuesday,...
- 5y agoTCDATricida Announces Multiple Data Presentations to Be Given at the Virtual National Kidney Foundation 2021 Spring Clinical MeetingsGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug...
- 5y agoTCDATricida Granted Additional U.S. Patent Covering Composition of Matter of VeverimerGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug...
- 5y agoTCDATricida Announces Fourth Quarter and Full Year 2020 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug...
- 5y agoTCDATricida Provides Update on FDA InteractionsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug...
- 5y agoTCDATricida to Report Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call and Webcast on Thursday, February 25, 2021GlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its fourth quarter and year-end 2020 financial results after the close...
- 5y agoTCDALAWSUIT FILED: Tricida, Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton LLPGlobeNewswireBOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Nationally-recognized securities law firm Block & Leviton LLP (www.blockleviton.com) announces that a lawsuit for violation of the federal securities...
- 5y agoTCDALAWSUIT FILED: Tricida, Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton LLPGlobeNewswireBOSTON, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Nationally-recognized securities law firm Block & Leviton LLP (www.blockleviton.com) announces that a lawsuit for violation of the federal securities...
- 5y agoTCDATricida to Present at the 39th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday,...
- 5y agoTCDATricida Announces Updates on Veverimer Development Program, Regulatory Status and New Patent Extending Protection through 2038GlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug...
- 5y agoTCDATricida to Provide an End-of-Year Business UpdateGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug...
- 6y agoTCDATricida Announces Third Quarter 2020 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug...
- 6y agoTCDATricida Provides Update on FDA InteractionsBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it held an End-of-Review conference as a T ...
- 6y agoTCDATricida to Provide Update from its End-of-Review Type A Meeting with the FDABusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it will provide an update on its interactions with the U.S ...
- 6y agoTCDATricida Announces Twelve Data Presentations on Veverimer and Metabolic Acidosis to be Given at the Virtual American Society of Nephrology Kidney Week 2020Business WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it has authored or sponsored 12 presentati ...
- 6y agoTCDATricida Receives Complete Response Letter from the FDA for its New Drug Application for Veverimer for the Treatment of Metabolic Acidosis and Slowing of Kidney Disease Progression in Patients with Metabolic Acidosis Associated with CKDBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it received a Complete Response Letter (CRL) from the U.S. ...
- 6y agoTCDATricida Announces Second Quarter 2020 Financial ResultsBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today financial results for the three and six months ended June 30, 2 ...
- 6y agoTCDATricida to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on Wednesday, August 5, 2020Business WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its second quarter 2020 financial results after the close of market on Wednesday, August 5, 2020. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its financial results and business progress. The call or webcast may be accessed as follows:
- 6y agoTCDATricida Provides Regulatory Update on VeverimerBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that on July 14, 2020, the Company received a notification from ...
- 6y agoTCDATricida Announces that 2020 Annual Meeting Will be Held in Virtual FormatBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (Nasdaq: TCDA) announced that, due to public health concerns relating to the coronavirus pandemic (COVID-19) and to protect the health of its employees, directors and stockholders, its 2020 annual meeting of stockholders (the “Annual Meeting”) will be held in a virtual-only format.
- 6y agoTCDATricida to Present at the Goldman Sachs Virtual Healthcare ConferenceBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020 at 1:40 pm PT / 4:40 pm ET. Tricida will provide a company overview, business update and progress on the company’s key initiatives.
- 6y agoTCDATricida Announces Closing of Offering of $200 Million of 3.50% Convertible Senior Notes Due 2027, Including Full Exercise of Option to Purchase Additional NotesBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (Nasdaq: TCDA) , a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), today announced the closing of its previously announced offering of $200.0 mil ...
- 6y agoTCDATricida Prices Offering of $175 Million 3.50% Convertible Senior Notes Due 2027Business WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), today announced the pricing of its offering of $175.0 million aggregate princip ...
- 6y agoTCDATricida Announces Proposed Offering of $175 Million Convertible Senior Notes Due 2027Business WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (Nasdaq: TCDA) today announced that it intends to offer $175.0 million aggregate principal amount of its Convertible Senior Notes due 2027 (the “Notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the ...